Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 16

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 16
---
;” |

| • |     | 2,557 Series B-1 common stock warrants to purchase 2,557 shares of our common stock of which 2,557 Series B-1                                                                                                           
 common stock warrants remain to be exercised as of June 30, 2025, with an exercise price of $0.28 per share, as more fully described in the section titled “Description of Capital Stock—Warrants—Series B-1 Warrants;” |

| • |     | 3,509 New Series B common stock warrants to purchase 3,509 shares of our common stock of which 3,509 New Series B                                                                                                          
 common stock warrants remain to be exercised as of June 30, 2025, with an exercise price of $41.84 per share, as more fully described in the section titled “Description of Capital Stock—Warrants—New Series B Warrants;” |

| • |     | 2,907,335 shares of common stock reserved for future issuance under our 2025 Equity Incentive Plan, or 2025 Plan,                                                                                                                                     
 which became effective upon the execution and delivery of the underwriting agreement for this offering (of which we will grant certain options to purchase shares of common stock at an exercise price equal to the initial public offering price, as 
 described in the section titled “Executive Compensation—2025 Equity Incentive Plan”), as well as any future automatic annual increases in the number of shares of common stock reserved for issuance under our 2025 Plan, as more fully               
 described in the section titled “Executive Compensation—Equity Benefit Plans;” and                                                                                                                                                                    |

| • |     | 201,000 shares of common stock reserved for future issuance under our 2025 Employee Stock Purchase Plan, or ESPP,                                                                                                                                     
 which became effective upon the execution and delivery of the underwriting agreement for this offering, as well as any future automatic annual increases in the number of shares of common stock reserved for future issuance under our ESPP, as more 
 fully described in the section titled “Executive Compensation—Equity Benefit Plans.”                                                                                                                                                                  |

In September 2025, our board of directors approved the repricing of stock options previously granted to current executive officers, employees and directors with per-share exercise prices above the initial per share to the public in this offering, or the Option Repricing. Assuming an initial price per share to the public in this offering of $15.00 per share, which is the midpoint of the price range